$18.600
+0.253 (+1.36%)Al cierre
- Máximo
- 20.000
- Apertura
- 19.020
- Precio medio ponderado por volumen
- 19.00
- Volumen
- 11.96K
- Capitalización
- —
- Mínimo
- 18.400
- Importe
- 227.20K
- EV/EBITDA, TTM
- 0.00
Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways. The company was incorporated in 2025 and is based in Sacramento, California.
Métricas de valoración
Cronología de eventos
Noticias
Preguntas frecuentes sobre MTRI, respondidas por Alphio AI
Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways. The company was incorporated in 2025 and is based in Sacramento, California.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- Dollar-Cost Averaging vs Lump Sum: How to Invest Cash in a Volatile, High-Yield 2026 MarketDollar cost averaging vs lump sum in a volatile 2026 market: what Vanguard's research shows, how 4%+ T-bill yields change the math, and how to build a plan.
- Stock Market Outlook 2027: What Wall Street's S&P 500 Forecasts Really Tell InvestorsStock market outlook 2027: what Goldman, UBS, BofA and bears forecast for the S&P 500, the earnings math behind targets, and how to plan for any scenario.
- REITs and Rising Interest Rates in 2026: Why Real Estate Stocks Are Holding Up and Where the Risks AHow rising interest rates affect REITs in 2026: why REITs are up despite Fed hikes, which sectors hold up, how to value REITs and build a rate-aware allocation.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.